News | January 24, 2025
Alivus Life Sciences delivers 12% revenue growth
EBITDA margins expand to 31.3%
EBITDA margins expand to 31.3%
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
With over 28 years of experience in the pharmaceutical industry, he is a seasoned Techno? Commercial professional and accomplished top management leader
Increases speed to market for drug developers working on nucleic acid therapeutics
Lilly plans to hire approximately more than 1,000 new highly-skilled team members
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Subscribe To Our Newsletter & Stay Updated
